Latest Insider Transactions at Surface Oncology, Inc. (SURF)
This section provides a real-time view of insider transactions for Surface Oncology, Inc. (SURF). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Surface Oncology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Surface Oncology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 08
2023
|
Alison Oneill Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
56,686
-100.0%
|
-
|
|
Sep 08
2023
|
David S. Grayzel Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,945,453
-100.0%
|
-
|
|
Sep 08
2023
|
Robert W. Ross Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
83,193
-100.0%
|
-
|
|
Sep 08
2023
|
Jessica Fees Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
101,915
-100.0%
|
-
|
|
Sep 08
2023
|
Jeff Goater Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
129,222
-100.0%
|
-
|
|
Sep 08
2023
|
Vito J. Palombella Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
87,212
-100.0%
|
-
|
|
Sep 08
2023
|
Henry C. Rath Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
44,971
-100.0%
|
-
|
|
Sep 08
2023
|
Chandra Adams Deputy GC |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,884
-100.0%
|
-
|
|
Sep 08
2023
|
Charles Elliott Sigal Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
45,453
-100.0%
|
-
|
|
Aug 01
2023
|
Robert W. Ross Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,713
-16.73%
|
$0
$0.94 P/Share
|
|
Aug 01
2023
|
Alison Oneill Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,042
-11.05%
|
$0
$0.94 P/Share
|
|
Aug 01
2023
|
Jessica Fees Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,434
-8.47%
|
$0
$0.94 P/Share
|
|
Aug 01
2023
|
Chandra Adams Deputy GC |
SELL
Open market or private sale
|
Direct |
3,901
-11.21%
|
$0
$0.94 P/Share
|
|
Aug 03
2022
|
Vito J. Palombella Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,463
-4.87%
|
$4,463
$1.72 P/Share
|
|
Aug 03
2022
|
Jessica Fees Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,980
-5.1%
|
$5,980
$1.72 P/Share
|
|
Aug 03
2022
|
Robert W. Ross Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,594
-9.59%
|
$10,594
$1.72 P/Share
|
|
Aug 03
2022
|
Alison Oneill Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,463
-6.54%
|
$4,463
$1.72 P/Share
|
|
Aug 03
2022
|
Henry C. Rath Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,676
-14.94%
|
$5,676
$1.72 P/Share
|
|
Mar 01
2022
|
Vito J. Palombella Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,000
+29.3%
|
-
|
|
Mar 01
2022
|
Jessica Fees Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,000
+24.46%
|
-
|
|
Mar 01
2022
|
Henry C. Rath Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,000
+50.0%
|
-
|
|
Mar 01
2022
|
Alison Oneill Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,000
+35.78%
|
-
|
|
Mar 01
2022
|
Robert W. Ross Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,000
+33.63%
|
-
|
|
Jul 21
2021
|
Liisa I Nogelo Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
26,325
-32.91%
|
$157,950
$6.1 P/Share
|
|
Jul 21
2021
|
Robert W. Ross Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
33,500
-38.07%
|
$201,000
$6.1 P/Share
|
|
Jul 21
2021
|
Vito J. Palombella Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
26,325
-32.91%
|
$157,950
$6.1 P/Share
|
|
Jul 21
2021
|
Jessica Fees Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
19,854
-20.02%
|
$119,124
$6.1 P/Share
|
|
Jul 21
2021
|
Jeff Goater Director |
SELL
Open market or private sale
|
Direct |
127,778
-49.72%
|
$766,668
$6.1 P/Share
|
|
Jul 21
2021
|
Alison Oneill Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
14,809
-32.91%
|
$88,854
$6.1 P/Share
|
|
Jun 11
2021
|
Jeff Goater Director |
SELL
Open market or private sale
|
Direct |
15,273
-5.61%
|
$106,911
$7.61 P/Share
|
|
Jun 11
2021
|
Jeff Goater Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,273
+3.64%
|
$41,092
$4.14 P/Share
|
|
Jun 10
2021
|
Jeff Goater Director |
SELL
Open market or private sale
|
Direct |
234,727
-47.25%
|
$1,643,089
$7.66 P/Share
|
|
Jun 10
2021
|
Jeff Goater Director |
BUY
Exercise of conversion of derivative security
|
Direct |
234,727
+18.37%
|
$938,908
$4.14 P/Share
|
|
Feb 16
2021
|
Robert W. Ross Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.12%
|
$11,000
$11.35 P/Share
|
|
Feb 08
2021
|
Jeff Goater Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.95%
|
$30,000
$12.5 P/Share
|
|
Feb 08
2021
|
Jeff Goater Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.94%
|
$7,500
$3.18 P/Share
|
|
Feb 08
2021
|
Jessica Fees Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,500
-1.49%
|
$18,000
$12.45 P/Share
|
|
Feb 01
2021
|
Jessica Fees Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,500
-1.47%
|
$16,500
$11.19 P/Share
|
|
Feb 01
2021
|
Jeff Goater Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.95%
|
$25,000
$10.69 P/Share
|
|
Feb 01
2021
|
Jeff Goater Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.94%
|
$7,500
$3.18 P/Share
|
|
Jan 19
2021
|
Jeff Goater Director |
SELL
Open market or private sale
|
Direct |
5,000
-1.87%
|
$65,000
$13.0 P/Share
|
|
Jan 19
2021
|
Jeff Goater Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.84%
|
$15,000
$3.18 P/Share
|
|
Jan 15
2021
|
Robert W. Ross Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,000
-2.2%
|
$24,000
$12.25 P/Share
|
|
Jan 14
2021
|
Robert W. Ross Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,000
-7.14%
|
$77,000
$11.95 P/Share
|
|
Dec 17
2020
|
David S. Grayzel Director |
SELL
Open market or private sale
|
Indirect |
1,700,000
-36.59%
|
$30,600,000
$18.1 P/Share
|
|
Dec 17
2020
|
Atlas Venture Fund Ix, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,700,000
-36.59%
|
$30,600,000
$18.1 P/Share
|
|
Dec 15
2020
|
Robert W. Ross Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.01%
|
$10,000
$10.48 P/Share
|
|
Dec 11
2020
|
Robert W. Ross Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,405
-1.4%
|
$14,050
$10.05 P/Share
|
|
Nov 25
2020
|
Jessica Fees Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,383
+0.34%
|
$5,532
$4.52 P/Share
|
|
Nov 11
2020
|
Robert W. Ross Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
595
-0.59%
|
$5,950
$10.05 P/Share
|